Avutometinib
- Generic Name
- Avutometinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H18FN5O5S
- CAS Number
- 946128-88-7
- Unique Ingredient Identifier
- D0D4252V97
- Background
Avutometinib (RO-5126766 free base) is under investigation in clinical trial NCT03875820 (Phase I Trial of VS-6063 and RO5126766.).
- Associated Conditions
- -
- Associated Therapies
- -
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 182
- Registration Number
- NCT06630260
- Locations
- π¬π§
Cambridge University Hospitals, Cambridge, United Kingdom
π¬π§The Royal Marsden Hospital - Drug Development Unit, Sutton, United Kingdom
π¬π§The Royal Marsden Hospital - Neuro-Oncology Unit, Sutton, United Kingdom
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Emory University
- Target Recruit Count
- 50
- Registration Number
- NCT06495125
- Locations
- πΊπΈ
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
πΊπΈEmory University Hospital Midtown, Atlanta, Georgia, United States
πΊπΈEmory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Avutometinib and Defactinib in Diffuse Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Ryan H. Moy, MD, PhD
- Target Recruit Count
- 27
- Registration Number
- NCT06487221
- Locations
- πΊπΈ
Columbia University Irving Medical Center, New York, New York, United States
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06394804
- Locations
- πΊπΈ
Emory Winship Cancer Institute, Atlanta, Georgia, United States
πΊπΈMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT06369259
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 33
- Registration Number
- NCT06194929
- Locations
- πΊπΈ
Huntsman Cancer Institute, Salt Lake City, Utah, United States
A Study of Avutometinib for People With Solid Tumor Cancers
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06104488
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
πΊπΈChildren's Healthcare of Atlanta (Data Collection Only), Atlanta, Georgia, United States
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06072781
- Locations
- πΊπΈ
Texas Oncology Central, Austin, Texas, United States
πΊπΈTexas Oncology-Fort Worth Cancer Center, Fort Worth, Texas, United States
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06007924
- Locations
- πΊπΈ
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
πΊπΈMemorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
πΊπΈMemorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre, New York, United States
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 12
- Registration Number
- NCT05798507
- Locations
- πΊπΈ
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.